SG10201912908QA - Combination therapy using a liv1-adc and a chemotherapeutic - Google Patents
Combination therapy using a liv1-adc and a chemotherapeuticInfo
- Publication number
- SG10201912908QA SG10201912908QA SG10201912908QA SG10201912908QA SG10201912908QA SG 10201912908Q A SG10201912908Q A SG 10201912908QA SG 10201912908Q A SG10201912908Q A SG 10201912908QA SG 10201912908Q A SG10201912908Q A SG 10201912908QA SG 10201912908Q A SG10201912908Q A SG 10201912908QA
- Authority
- SG
- Singapore
- Prior art keywords
- liv1
- chemotherapeutic
- adc
- combination therapy
- therapy
- Prior art date
Links
- 230000000973 chemotherapeutic effect Effects 0.000 title 1
- 238000002648 combination therapy Methods 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/68031—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being an auristatin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3015—Breast
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201662308639P | 2016-03-15 | 2016-03-15 | |
US201662317792P | 2016-04-04 | 2016-04-04 | |
US201662367510P | 2016-07-27 | 2016-07-27 |
Publications (1)
Publication Number | Publication Date |
---|---|
SG10201912908QA true SG10201912908QA (en) | 2020-02-27 |
Family
ID=59852409
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG10201912908QA SG10201912908QA (en) | 2016-03-15 | 2017-03-15 | Combination therapy using a liv1-adc and a chemotherapeutic |
SG11201807526SA SG11201807526SA (en) | 2016-03-15 | 2017-03-15 | Combination therapy using a liv1-adc and a chemotherapeutic |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11201807526SA SG11201807526SA (en) | 2016-03-15 | 2017-03-15 | Combination therapy using a liv1-adc and a chemotherapeutic |
Country Status (14)
Country | Link |
---|---|
US (2) | US11325980B2 (en) |
EP (1) | EP3429626A4 (en) |
JP (2) | JP2019508433A (en) |
KR (3) | KR20180121571A (en) |
CN (1) | CN108697801A (en) |
AU (2) | AU2017235545A1 (en) |
BR (1) | BR112018068129A2 (en) |
CA (1) | CA3016485A1 (en) |
EA (1) | EA201891968A1 (en) |
IL (1) | IL261505A (en) |
MA (1) | MA45324A (en) |
MX (2) | MX2018010847A (en) |
SG (2) | SG10201912908QA (en) |
WO (1) | WO2017161007A1 (en) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PT3156420T (en) | 2010-12-06 | 2019-05-27 | Seattle Genetics Inc | Humanized antibodies to liv-1 and use of same to treat cancer |
MX2020005640A (en) * | 2017-12-01 | 2020-08-20 | Seattle Genetics Inc | Humanized anti-liv1 antibodies for the treatment of breast cancer. |
CA3118824A1 (en) * | 2018-11-07 | 2020-05-14 | Crispr Therapeutics Ag | Anti-liv1 immune cell cancer therapy |
US20210228676A1 (en) * | 2019-12-09 | 2021-07-29 | Seagen Inc. | Combination Therapy With LIV1-ADC and PD-1 Antagonist |
Family Cites Families (60)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4880935A (en) | 1986-07-11 | 1989-11-14 | Icrf (Patents) Limited | Heterobifunctional linking agents derived from N-succinimido-dithio-alpha methyl-methylene-benzoates |
IL89220A (en) | 1988-02-11 | 1994-02-27 | Bristol Myers Squibb Co | Anthracycline immunoconjugates, their production and pharmaceutical compositions containing them |
US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
CA2096417C (en) | 1991-08-22 | 2000-10-10 | Sarah S. Bacus | Methods and compositions for cancer therapy and for prognosticating responses to cancer therapy |
US5622929A (en) | 1992-01-23 | 1997-04-22 | Bristol-Myers Squibb Company | Thioether conjugates |
US6214345B1 (en) | 1993-05-14 | 2001-04-10 | Bristol-Myers Squibb Co. | Lysosomal enzyme-cleavable antitumor drug conjugates |
CA2132500A1 (en) | 1994-09-20 | 1996-03-21 | David Lockwood Manning | Methods for predicting the behaviour of breast tumours |
ES2195036T3 (en) | 1995-12-22 | 2003-12-01 | Bristol Myers Squibb Co | RAMIFIED HYDRAZONE CONNECTORS. |
US6130237A (en) | 1996-09-12 | 2000-10-10 | Cancer Research Campaign Technology Limited | Condensed N-aclyindoles as antitumor agents |
EP0939824B1 (en) | 1996-10-31 | 2007-06-06 | Abbott Laboratories | Reagents and methods useful for detecting diseases of the breast |
US6066778A (en) | 1996-11-06 | 2000-05-23 | The Regents Of The University Of Michigan | Transgenic mice expressing APC resistant factor V |
WO1998034118A1 (en) | 1997-01-30 | 1998-08-06 | Yale University | Diagnostic methods and compositions based on the distribution of rad51 |
JP2001521744A (en) | 1997-10-31 | 2001-11-13 | アボット・ラボラトリーズ | Reagents and methods useful for detecting breast disease |
WO1999025877A1 (en) | 1997-11-18 | 1999-05-27 | Abbott Laboratories | Reagents and methods useful for detecting diseases of the breast |
EP1042360A2 (en) | 1997-12-24 | 2000-10-11 | Corixa Corporation | Compounds for immunotherapy and diagnosis of breast cancer and methods for their use |
CA2347906A1 (en) | 1998-08-04 | 2000-02-17 | Diadexus, Inc. | A novel method of diagnosing, monitoring, staging, imaging and treating breast cancer |
EP1953229A3 (en) | 1998-10-15 | 2008-12-24 | Novartis Vaccines and Diagnostics, Inc. | Metastatic breast and colon cancer regulated genes |
AU3395900A (en) | 1999-03-12 | 2000-10-04 | Human Genome Sciences, Inc. | Human lung cancer associated gene sequences and polypeptides |
US6762020B1 (en) | 1999-03-15 | 2004-07-13 | Protein Design Labs, Inc. | Methods of diagnosing breast cancer |
US20040141983A1 (en) | 1999-03-15 | 2004-07-22 | Protein Design Labs, Inc. | Compositions against cancer antigen LIV-1 and uses thereof |
AU3458401A (en) | 2000-01-25 | 2001-08-07 | Genentech Inc. | Compositions and methods for treatment of cancer |
AU2001264099A1 (en) | 2000-06-13 | 2001-12-24 | University College Cardiff Consultants Ltd. | Zinc transporters |
US6964849B2 (en) | 2001-01-11 | 2005-11-15 | Curagen Corporation | Proteins and nucleic acids encoding same |
US6884869B2 (en) | 2001-04-30 | 2005-04-26 | Seattle Genetics, Inc. | Pentapeptide compounds and uses related thereto |
US7705120B2 (en) | 2001-06-21 | 2010-04-27 | Millennium Pharmaceuticals, Inc. | Compositions, kits, and methods for identification, assessment, prevention, and therapy of breast cancer |
US20030068636A1 (en) | 2001-06-21 | 2003-04-10 | Millennium Pharmaceuticals, Inc. | Compositions, kits and methods for identification, assessment, prevention, and therapy of breast and ovarian cancer |
US7091186B2 (en) | 2001-09-24 | 2006-08-15 | Seattle Genetics, Inc. | p-Amidobenzylethers in drug delivery agents |
PT1572087E (en) | 2002-03-08 | 2008-07-11 | Pdl Biopharma Inc | Antibodies against cancer antigen tmeff2 and uses thereof |
EP1545613B9 (en) | 2002-07-31 | 2012-01-25 | Seattle Genetics, Inc. | Auristatin conjugates and their use for treating cancer, an autoimmune disease or an infectious disease |
JP2006520194A (en) | 2003-01-27 | 2006-09-07 | バイオジェン・アイデック・エムエイ・インコーポレイテッド | Compositions and methods for treating cancer using IGSF9 and LIV-1 |
WO2004067564A2 (en) | 2003-01-29 | 2004-08-12 | Protein Design Labs, Inc. | Compositions against cancer antigen liv-1 and uses thereof |
SG195524A1 (en) | 2003-11-06 | 2013-12-30 | Seattle Genetics Inc | Monomethylvaline compounds capable of conjugation to ligands |
WO2005058961A2 (en) | 2003-12-12 | 2005-06-30 | Amgen Inc. | Antibodies specific for human galanin, and uses thereof |
US7501121B2 (en) | 2004-06-17 | 2009-03-10 | Wyeth | IL-13 binding agents |
US20060222653A1 (en) | 2004-11-12 | 2006-10-05 | Xencor, Inc. | Antibodies operably linked to selected chemoattractants |
WO2006124269A2 (en) | 2005-05-16 | 2006-11-23 | Amgen Fremont Inc. | Human monoclonal antibodies that bind to very late antigen-1 for the treatment of inflammation and other disorders |
AU2006287416A1 (en) | 2005-09-07 | 2007-03-15 | Medimmune, Llc | Toxin conjugated Eph receptor antibodies |
CN101309933A (en) * | 2005-09-07 | 2008-11-19 | 米迪缪尼有限公司 | Toxin conjugated eph receptor antibodies |
WO2007120787A2 (en) | 2006-04-13 | 2007-10-25 | Novartis Vaccines & Diagnostics, Inc. | Methods of treating, diagnosing or detecting cancers associated with liv-1 overexpression |
ES2523915T5 (en) | 2006-12-01 | 2022-05-26 | Seagen Inc | Variant Target Binding Agents and Uses Thereof |
CA2685123A1 (en) | 2007-04-23 | 2008-10-30 | Wyeth | Methods and compositions for treating and monitoring treatment of il-13-associated disorders |
US20110008345A1 (en) | 2007-11-30 | 2011-01-13 | Claire Ashman | Antigen-binding constructs |
US20110166838A1 (en) | 2008-06-16 | 2011-07-07 | Sividon Diagnostics | Algorithms for outcome prediction in patients with node-positive chemotherapy-treated breast cancer |
WO2010045234A1 (en) | 2008-10-14 | 2010-04-22 | University Of Louisville Research Foundation, Inc. | Methods of optimizing treatment of estrogen-receptor positive breast cancers |
WO2010069858A1 (en) | 2008-12-19 | 2010-06-24 | F. Hoffmann-La Roche Ag | Pharmaceutical composition |
US8642270B2 (en) | 2009-02-09 | 2014-02-04 | Vm Institute Of Research | Prognostic biomarkers to predict overall survival and metastatic disease in patients with triple negative breast cancer |
US20110165566A1 (en) | 2009-07-09 | 2011-07-07 | Wittliff James L | Methods of optimizing treatment of breast cancer |
JP5996429B2 (en) | 2009-09-03 | 2016-09-21 | ジェネンテック, インコーポレイテッド | Method for treatment, diagnosis and monitoring of rheumatoid arthritis |
PT3156420T (en) * | 2010-12-06 | 2019-05-27 | Seattle Genetics Inc | Humanized antibodies to liv-1 and use of same to treat cancer |
WO2012125712A2 (en) | 2011-03-14 | 2012-09-20 | Respira Health, Llc | Lung tumor classifier for current and former smokers |
PL2766040T3 (en) | 2011-10-14 | 2019-11-29 | Hoffmann La Roche | Pertuzumab, trastuzumab, docetaxel and carboplatin for the treatment of early-stage breast cancer |
AU2013259053A1 (en) * | 2012-05-11 | 2015-01-15 | Merrimack Pharmaceuticals, Inc. | Dosage and administration of bispecific scFv conjugates in combination with anti-cancer therapeutics |
DE202012006349U1 (en) | 2012-07-03 | 2013-07-05 | Schuster Engineering Gmbh | Ship loading assembly |
SI2839860T1 (en) | 2012-10-12 | 2019-07-31 | MedImmune Limited, | Pyrrolobenzodiazepines and conjugates thereof |
WO2015002134A1 (en) | 2013-07-02 | 2015-01-08 | 公益財団法人がん研究会 | Cellular immunity inducing vaccine |
ES2754348T3 (en) | 2014-04-10 | 2020-04-17 | Daiichi Sankyo Co Ltd | Conjugate of (anti-HER2 antibody) -pharmaceutical |
MX2020005640A (en) | 2017-12-01 | 2020-08-20 | Seattle Genetics Inc | Humanized anti-liv1 antibodies for the treatment of breast cancer. |
CA3118824A1 (en) | 2018-11-07 | 2020-05-14 | Crispr Therapeutics Ag | Anti-liv1 immune cell cancer therapy |
GB201908208D0 (en) | 2019-06-10 | 2019-07-24 | Univ College Cardiff Consultants Ltd | An anti-mitotic agent |
US20210228676A1 (en) | 2019-12-09 | 2021-07-29 | Seagen Inc. | Combination Therapy With LIV1-ADC and PD-1 Antagonist |
-
0
- MA MA045324A patent/MA45324A/en unknown
-
2017
- 2017-03-15 EP EP17767448.8A patent/EP3429626A4/en active Pending
- 2017-03-15 KR KR1020187028273A patent/KR20180121571A/en active Application Filing
- 2017-03-15 MX MX2018010847A patent/MX2018010847A/en unknown
- 2017-03-15 JP JP2018546036A patent/JP2019508433A/en active Pending
- 2017-03-15 KR KR1020237041743A patent/KR20230169462A/en active Application Filing
- 2017-03-15 CN CN201780013873.8A patent/CN108697801A/en active Pending
- 2017-03-15 SG SG10201912908QA patent/SG10201912908QA/en unknown
- 2017-03-15 US US16/085,511 patent/US11325980B2/en active Active
- 2017-03-15 WO PCT/US2017/022541 patent/WO2017161007A1/en active Application Filing
- 2017-03-15 SG SG11201807526SA patent/SG11201807526SA/en unknown
- 2017-03-15 EA EA201891968A patent/EA201891968A1/en unknown
- 2017-03-15 BR BR112018068129A patent/BR112018068129A2/en active Search and Examination
- 2017-03-15 AU AU2017235545A patent/AU2017235545A1/en not_active Abandoned
- 2017-03-15 CA CA3016485A patent/CA3016485A1/en active Pending
- 2017-03-15 KR KR1020227039721A patent/KR20220157515A/en active Application Filing
-
2018
- 2018-09-02 IL IL261505A patent/IL261505A/en unknown
- 2018-09-07 MX MX2023008849A patent/MX2023008849A/en unknown
-
2022
- 2022-01-20 JP JP2022006944A patent/JP2022058676A/en active Pending
- 2022-10-17 US US18/047,243 patent/US20230235083A1/en active Pending
-
2024
- 2024-03-21 AU AU2024201856A patent/AU2024201856A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
KR20230169462A (en) | 2023-12-15 |
AU2024201856A1 (en) | 2024-04-11 |
BR112018068129A2 (en) | 2019-01-15 |
MX2018010847A (en) | 2019-07-04 |
US20190085091A1 (en) | 2019-03-21 |
EP3429626A4 (en) | 2020-05-06 |
KR20220157515A (en) | 2022-11-29 |
MX2023008849A (en) | 2023-08-15 |
US11325980B2 (en) | 2022-05-10 |
CA3016485A1 (en) | 2017-09-21 |
JP2019508433A (en) | 2019-03-28 |
SG11201807526SA (en) | 2018-09-27 |
MA45324A (en) | 2019-01-23 |
US20230235083A1 (en) | 2023-07-27 |
JP2022058676A (en) | 2022-04-12 |
IL261505A (en) | 2018-10-31 |
AU2017235545A1 (en) | 2018-10-25 |
CN108697801A (en) | 2018-10-23 |
WO2017161007A1 (en) | 2017-09-21 |
EA201891968A1 (en) | 2019-02-28 |
EP3429626A1 (en) | 2019-01-23 |
KR20180121571A (en) | 2018-11-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL263521A (en) | Combination therapy | |
GB201707153D0 (en) | Therapy | |
IL265406B (en) | Combination therapy | |
GB201609597D0 (en) | Therapy | |
IL261505A (en) | Combination therapy using a liv1-adc and a chemotherapeutic | |
GB201719646D0 (en) | Therapy | |
HK1247619A1 (en) | Combination therapy using a cd19-adc and vincristine | |
GB201604318D0 (en) | Combination therapy | |
GB201604316D0 (en) | Combination therapy | |
IL265340A (en) | Combination therapy | |
GB201609735D0 (en) | Combination therapy | |
GB201603653D0 (en) | Combination Therapy | |
EP3487525A4 (en) | Combination therapy using a cd19-adc and rchp | |
GB201715430D0 (en) | Therapy | |
GB201707945D0 (en) | Cnacer therapy | |
GB201707183D0 (en) | Macrophage-based therapy | |
GB201618477D0 (en) | Therapy | |
GB201703453D0 (en) | Therapy | |
GB201706228D0 (en) | Combination therapy | |
GB201706225D0 (en) | Combination therapy | |
GB201706227D0 (en) | Combination therapy | |
GB201706229D0 (en) | Combination therapy | |
GB201706222D0 (en) | Combination therapy | |
GB201706223D0 (en) | Combination therapy | |
GB201706224D0 (en) | Combination therapy |